BBP-398
- Generic Name
- BBP-398
BBP-398 in Combination With Osimertinib in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutations
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- LianBio LLC
- Target Recruit Count
- 4
- Registration Number
- NCT06032936
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guanzhou, Guangdong, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Jilin Cancer Hospital, Changchun, Jilin, China
Phase I Study of the BBP-398 in Patients With Advance Solid Tumors
Phase 1
Terminated
- Conditions
- Advanced Solid TumorAdvanced or Metastatic Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2022-11-18
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- LianBio LLC
- Target Recruit Count
- 7
- Registration Number
- NCT05621525
- Locations
- 🇨🇳
West China Hospital Sichuan University, Chengdu, Sichuan, China
🇨🇳Sun Yat-sen University Cancer Center, Guanzhou, Guangdong, China
SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation
Phase 1
Terminated
- Conditions
- Metastatic Solid TumorMetastatic NSCLCNon Small Cell Lung CancerSolid Tumor, Adult
- Interventions
- First Posted Date
- 2022-07-29
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Navire Pharma Inc., a BridgeBio company
- Target Recruit Count
- 28
- Registration Number
- NCT05480865
- Locations
- 🇦🇺
Cancer Research SA, Adelaide, South Australia, Australia
🇦🇺Southern Oncology Clinical Research Unit, Adelaide, South Australia, Australia
🇦🇺Peninsula & South Eastern Haematology and Oncology Group, Frankston, Victoria, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath